Literature DB >> 22460843

Osteoporosis and cardiovascular disease: lessons from chronic kidney disease.

Keith A Hruska1, Suresh Mathew, Richard Lund.   

Abstract

Osteoporosis is a common complication of chronic kidney disease (CKD), and the latter is a major risk factor for cardiovascular mortality. Recent studies have elucidated some of the mechanisms by which CKD is a cardiovascular risk, and they relate to osteoporosis. Thus, the mechanisms of CKD induced cardiovascular risk provide valuable insight into the relationship between cardiovascular disease and osteoporosis, and they are reviewed here. Observational studies have determined hyperphosphatemia to be a cardiovascular risk factor in chronic kidney disease. Mechanistic studies have elucidated that hyperphosphatemia is a direct stimulus to vascular calcification, which is one cause of morbid cardiovascular events contributing to the excess mortality of chronic kidney disease. Hyperphosphatemia in chronic kidney is due to failure of excretion by the kidneys and excess bone resorption. It stimulates vascular cells to mineralize atherosclerotic plaques through osteoblastic processes. Hyperphosphatemia in chronic kidney disease is a distinct syndrome characterized by disordered skeletal remodeling, heterotopic mineralization and cardiovascular morbidity. The heterotopic mineralization stimulated by CKD is relevant to osteoporosis.

Entities:  

Year:  2008        PMID: 22460843      PMCID: PMC2781186     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  50 in total

1.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.

Authors:  M Coco; H Rush
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

Review 2.  Osteoporosis in chronic kidney disease.

Authors:  John Cunningham; Stuart M Sprague; Jorge Cannata-Andia; Maria Coco; Martine Cohen-Solal; Lorraine Fitzpatrick; David Goltzmann; Marie-Helene Lafage-Proust; Mary Leonard; Susan Ott; Mariano Rodriguez; Catherine Stehman-Breen; Paula Stern; Jose Weisinger
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

3.  Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Authors:  Lourdes Craver; Maria Paz Marco; Isabel Martínez; Montserrat Rue; Merce Borràs; Maria Luisa Martín; Felipe Sarró; José Manuel Valdivielso; Elvira Fernández
Journal:  Nephrol Dial Transplant       Date:  2007-01-05       Impact factor: 5.992

4.  Racial differences in bone mineral density and bone loss among end-stage renal disease patients.

Authors:  C O Stehman-Breen; D Sherrard; A Walker; R Sadler; A Alem; J Lindberg
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

Review 5.  Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism.

Authors:  I B Salusky; W G Goodman; B D Kuizon
Journal:  Pediatr Nephrol       Date:  2000-07       Impact factor: 3.714

6.  Increased risk of hip fracture among patients with end-stage renal disease.

Authors:  A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

7.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

8.  Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification.

Authors:  Ricardo Villa-Bellosta; Yolanda E Bogaert; Moshe Levi; Víctor Sorribas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-22       Impact factor: 8.311

9.  Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

Authors:  Sharon M Moe; Danxia Duan; Brian P Doehle; Kalisha D O'Neill; Neal X Chen
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

10.  Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

Authors:  M Wang; G Hercz; D J Sherrard; N A Maloney; G V Segre; Y Pei
Journal:  Am J Kidney Dis       Date:  1995-11       Impact factor: 8.860

View more
  3 in total

1.  Impact of altered dietary calcium-phosphorus ratio caused by high-phosphorus diets in a rat chronic kidney disease (CKD) model created by partial ligation of the renal arteries.

Authors:  Atsushi Watanabe; Toshinori Koizumi; Takumi Horikawa; Yusuke Sano; Haruka Uki; Katsuhiro Miyajima; Noriko Kemuriyama; Reo Anzai; Hijiri Iwata; Takayuki Anzai; Kenshi Nakagawa; Dai Nakae
Journal:  J Toxicol Pathol       Date:  2020-01-03       Impact factor: 1.628

2.  Low bone mineral density is associated with coronary arterial calcification progression and incident cardiovascular events in patients with chronic kidney disease.

Authors:  Hyoungnae Kim; Joongyub Lee; Kyu-Beck Lee; Yeong-Hoon Kim; Namki Hong; Jung Tak Park; Seung Hyeok Han; Shin-Wook Kang; Kyu Hun Choi; Kook-Hwan Oh; Tae-Hyun Yoo
Journal:  Clin Kidney J       Date:  2021-07-23

3.  Machine Learning Algorithms: Prediction and Feature Selection for Clinical Refracture after Surgically Treated Fragility Fracture.

Authors:  Hirokazu Shimizu; Ken Enda; Tomohiro Shimizu; Yusuke Ishida; Hotaka Ishizu; Koki Ise; Shinya Tanaka; Norimasa Iwasaki
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.